Joshi Abhay 4
4 · Revance Therapeutics, Inc. · Filed Feb 17, 2022
Insider Transaction Report
Form 4
Joshi Abhay
Chief Operating Officer
Transactions
- Tax Payment
Common Stock
2022-02-15$13.35/sh−2,151$28,716→ 126,217 total - Tax Payment
Common Stock
2022-02-15$13.35/sh−2,902$38,742→ 123,315 total
Footnotes (2)
- [F1]Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock award ("RSA") for 15,750 shares. The RSA vests in three equal annual installments from February 15, 2019, subject to Dr. Joshi's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan.")) on each vesting date.
- [F2]Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of an RSA for 25,000 shares. The RSA vests in three equal annual installments from February 15, 2020, subject to Dr. Joshi's Continuous Service (as defined in the Plan) on each vesting date.